Genetic variation in genes for the xenobiotic-metabolizing enzymes CYP1A1, EPHX1, GSTM1, GSTT1, and GSTP1 and susceptibility to colorectal cancer in lynch syndrome

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 9, 2008, Pages 2393-2401

  Pande, Mala ^a   Amos, Christopher I ^a,b   Osterwisch, Daniel R ^a   Chen, Jinyun ^a   Lynch, Patrick M ^a   Broaddus, Russell ^a   Frazier, Marsha L ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; EPHX1 PROTEIN; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ADULT; ARTICLE; CANCER RISK; COLORECTAL CANCER; FAMILIAL CANCER; FEMALE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WILD TYPE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CYTOCHROME P-450 CYP1A1; EPOXIDE HYDROLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VARIATION (GENETICS);

EID: 53349129594     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0326     Document Type: Article

References (37)

1. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-32.
2. Watson P, Riley B. The tumor spectrum in the Lynch syndrome. Fam Cancer 2005;4:245-8.
3. Peltomaki P, Gao X, Mecklin JP. Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations. Fam Cancer 2001;1:9-15.
4. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004;4:769-80.
5. Lynch HT, Lynch JF. Lynch syndrome: history and current status. Dis Markers 2004;20:181-98.
6. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006;6:947-60.
7. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995;25:27-65.
8. Mercurio MG, Shiff SJ, Galbraith RA, Sassa S. Expression of cytochrome P450 mRNAs in the colon and the rectum in normal human subjects. Biochem Biophys Res Commun 1995;210:350-5.
9. de Jong MM, Nolte IM, te Meerman GJ, et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2002;11:1332-52.
10. Slattery ML, Samowtiz W, Ma K, et al. CYP1A1, cigarette smoking, and colon and rectal cancer. Am J Epidemiol 2004;160:842-52.
11. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Genetic polymorphisms in xenobiotic clearance genes and their influence on disease expression in hereditary nonpolyposis colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2006;15:2307-10.
12. Gsur A, Zidek T, Schnattinger K, et al. Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer 2003;89:702-6.
13. Landi S, Gemignani F, Moreno V, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 2005;15:535-46.
14. Robien K, Curtin K, Ulrich CM, et al. Microsomal epoxide hydrolase polymorphisms are not associated with colon cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:1350-2.
15. Whalen R, Boyer TD. Human glutathione S-transferases. Semin Liver Dis 1998;18:345-58.
16. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-6.
17. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997;6:733-43.
18. Felix R, Bodmer W, Fearnhead NS, van der ML, Goldberg P, Ramesar RS. GSTM1 and GSTT1 polymorphisms as modifiers of age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a homogeneous cohort of individuals carrying a single predisposing mutation. Mutat Res 2006;602:175-81.
19. Moisio AL, Sistonen P, Mecklin JP, Jarvinen H, Peltomaki P. Genetic polymorphisms in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. Gastroenterology 1998;115:1387-94.
20. Jones JS, Gu X, Campos IM, Lynch PM, Amos CI, Frazier ML. GSTM1 polymorphism does not affect hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomarkers Prev 2004;13:676-8.
21. Heinimann K, Scott RJ, Chappuis P, et al. N-acetyltransferase 2 influences cancer prevalence in hMLH1/hMSH2 mutation carriers. Cancer Res 1999;59:3038-40.
22. Chen J, Sen S, Amos CI, et al. Association between Aurora-A kinase polymorphisms and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Mol Carcinog 2007;46:249-56.
23. Frazier ML, O'Donnell FT, Kong S, et al. Age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes. Cancer Res 2001;61:1269-71.
24. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.
25. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med 2003;138:560-70.
26. Cravo M, Afonso AJ, Lage P, et al. Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing. Gut 2002;50:405-12.
27. Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 2005;129:537-49.
28. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006;354:2751-63.
29. Lagerstedt RK, Liu T, Vandrovcova J, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007;99:291-9.
30. Abdel-Rahman SZ, el Zein RA, Anwar WA, Au WW. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 1996;107:229-33.
31. Rogers WH. Regression standard errors in clustered samples. Stata Technical Bulletin 1993;13:19-23.
32. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics 2000;56:645-6.
33. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
34. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 2006;21:357-74.
35. Chen K, Jiang QT, He HQ. Relationship between metabolic enzyme polymorphism and colorectal cancer. World J Gastroenterol 2005;11:331-5.
36. Rajagopal R, Deakin M, Fawole AS, et al. Glutathione S-transferase T1 polymorphisms are associated with outcome in colorectal cancer. Carcinogenesis 2005;26:2157-63.
37. Huan WY, Chatterjee N, Chanock S, et al. Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2005;14:152-7.